EcoDrugPlus

Purinergic Receptor P2y2

Ensembl ID : ENSG00000175591
Gene: P2RY2
Gene Synonyms: P2U
2 APIs:
10 Enzyme and pathways 7 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSG00000186912
Gene: P2RY4
Gene Synonyms: NRU,P2P,P2Y4,UNR
1 APIs:
8 Enzyme and pathways 7 Cross references
168 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSG00000171631
Gene: P2RY6
Gene Synonyms: P2Y6
1 APIs:
8 Enzyme and pathways 7 Cross references
183 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Renin

Ensembl ID : ENSG00000143839
Gene: REN
Gene Synonyms:
2 APIs:
3 Enzyme and pathways 8 Cross references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ret Proto-Oncogene

Ensembl ID : ENSG00000165731
Gene: RET
Gene Synonyms: CDHF12,CDHR16,HSCR1,MEN2A,MEN2B,MTC1,PTC,RET51
14 APIs:
13 Enzyme and pathways 9 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoic Acid Receptor Alpha

Ensembl ID : ENSG00000131759
Gene: RARA
Gene Synonyms: NR1B1,RAR,RAR-ALPHA,RARALPHA
7 APIs:
16 Enzyme and pathways 9 Cross references
331 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoic Acid Receptor Beta

Ensembl ID : ENSG00000077092
Gene: RARB
Gene Synonyms: HAP,NR1B2,RAR-BETA,RARBETA,RRB2
6 APIs:
10 Enzyme and pathways 8 Cross references
451 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoic Acid Receptor Gamma

Ensembl ID : ENSG00000172819
Gene: RARG
Gene Synonyms: NR1B3,RAR-GAMMA,RARC,RARGAMMA
7 APIs:
10 Enzyme and pathways 7 Cross references
450 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoid X Receptor Alpha

Ensembl ID : ENSG00000186350
Gene: RXRA
Gene Synonyms: NR2B1,RXR-ALPHA,RXRALPHA
4 APIs:
57 Enzyme and pathways 7 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoid X Receptor Beta

Ensembl ID : ENSG00000204231
Gene: RXRB
Gene Synonyms: H-2RIIBP,NR2B2,RCOR-1,RXR-BETA,RXRBETA
2 APIs:
18 Enzyme and pathways 7 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Retinoid X Receptor Gamma

Ensembl ID : ENSG00000143171
Gene: RXRG
Gene Synonyms: NR2B3,RXR-GAMMA,RXRGAMMA
2 APIs:
7 Enzyme and pathways 7 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L10

Ensembl ID : ENSG00000147403
Gene: RPL10
Gene Synonyms: DXS648,DXS648E,FLJ23544,L10,NOV,QM
4 APIs:
36 Enzyme and pathways 8 Cross references
122 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).